Clinical trials: Painful Diabetic Peripheral Neuropathy
Painful Diabetic Neuropathy, Diabetic Neuropathy, Painful
Extension of Phase 3 Gene Therapy for Painful Diabetic Neuropathy
The purpose of this study is to explore the overall safety profile and durability of efficacy of Engensis (VM202) in painful diabetic peripheral neuropathy.
- Trial name
- NCT04055090
- Testing
- Long-Term Follow-Up of Patients who Received Engensis (VM202)
- Where
- 14 sites in United States
- Volunteers
- 101 people
- Sponsor
- Helixmith Co., Ltd.
Pain
[S,S]-Reboxetine Long Term Safety Study In Chronic Painful Diabetic Peripheral Neuropathy.
The purpose of this study is to assess the long-term safety and tolerability of [S,S]-Reboxetine in patients with chronic painful diabetic peripheral neuropathy
- Trial name
- NCT00348894
- Testing
- [S,S]-Reboxetine, Any
- Where
- 93 sites in United States, Argentina and 12 more
- Volunteers
- 136 people
- Sponsor
- Pfizer
Diabetic Peripheral Neuropathy
Efficacy and Safety Study of Pregabalin in the Treatment of Pain on Walking in Patients With Diabetic Peripheral Neuropathy (DPN)
The intent of this study is to treat subjects with painful Diabetic Peripheral Neuropathy (DPN) who also have pain on walking and to determine whether or not pregabalin demonstrates improvement relative to placebo on the…
- Trial name
- NCT01474772
- Testing
- Pregabalin
- Where
- 45 sites in United States, Czechia and 2 more
- Volunteers
- 217 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Fibromyalgia, Painful Diabetic Peripheral Neuropathy
Examination of Pregabalin Access for Treatment of Indicated Pain Disorders: the ExPAND Study
The investigators hypothesize that fibromyalgia (FM) and painful diabetic peripheral neuropathy (pDPN) patients with access restrictions on pregabalin will lead to higher healthcare resource use and cost compared to patients…
- Trial name
- NCT01280747
- Testing
- prior authorization, no prior authorization
- Where
- 17 sites in United States
- Volunteers
- 42 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Diabetic Peripheral Neuropathy, Neuralgia
A Study of the Efficacy and Safety of Amitriptyline/Ketamine Topical Cream in Patients With Diabetic Peripheral Neuropathy
This is a multicenter, randomized, placebo-controlled, parallel group study of EpiCept™ NP-1 Topical Cream (amitriptyline 4%/ketamine 2%) in approximately 200 patients with pain in the lower extremities due to diabetic nerve pain.
- Trial name
- NCT00476151
- Testing
- EpiCept NP-1 (4% Amitriptyline/ 2% Ketamine) Topical Cream
- Where
- India
- Volunteers
- 226 people
- Sponsor
- EpiCept Corporation
Diabetic Peripheral Neuropathy
Double Blind RCT of Bicifadine SR in Outpatients With Chronic Neuropathic Pain Associated With Diabetes
To compare the efficacy of two dosages (600mg/day and 1200mg/day) of bicifadine SR with placebo for 14 weeks in reduction of chronic neuropathic patin (measured by a daily rating of pain intensity) associated with diabetic…
- Trial name
- NCT00553592
- Testing
- Bicifadine
- Where
- United States
- Volunteers
- 336 people
- Sponsor
- XTL Biopharmaceuticals
Painful Diabetic Neuropathy, Diabetes
A Safety Study of Clonidine Hydrochloride Topical Gel, 0.1% in the Treatment of Painful Diabetic Neuropathy
Study CLO-311 is a multicenter, open-label, single-arm study to assess the long-term use of Clonidine Gel in the treatment of pain associated with PDN.
- Trial name
- NCT02355158
- Testing
- clonidine hydrochloride topical gel, 0.1%
- Where
- 20 sites in United States
- Volunteers
- 197 people
- Sponsor
- BioDelivery Sciences International
Diabetic Peripheral Neuropathic Pain
Using Cannabidiol to Treat Diabetic Peripheral Neuropathy of the Feet
The purpose of the study is to evaluate whether PG-DN-20WS is a better pain reliever in patients with diabetic neuropathic pain of the feet than a placebo.
- Trial name
- NCT04679545
- Testing
- CBD
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Pure Green
Diabetic Neuropathic Pain
A Randomized, Double-blind, Placebo- and Active-controlled Study of the Electric Current Effects of ABT-639 on the Spontaneous Activity of Pain Sensory Receptors in Patients With Diabetic Peripheral Neuropathy
People with diabetes can, over time develop nerve damage throughout the body with symptoms such as pain, tingling, or numbness (loss of feeling) in the hands, arms, feet and legs.
- Trial name
- NCT01589432
- Testing
- ABT-639, Lidocaine
- Where
- United Kingdom
- Volunteers
- 39 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Neuropathy, Diabetic, Neuropathy;Peripheral
Clinical Efficacy and Human Factors Validation Testing of the Erchonia EVRL for Providing Temporary Relief of Diabetic Peripheral Neuropathy Foot Pain
The purpose of this clinical study is to determine the effectiveness of the Erchonia® EVRL™, manufactured by Erchonia Corporation (the Company), in providing prescription home use application for temporary relief of diabetic…
- Conditions
- Neuropathy, Diabetic, Neuropathy;Peripheral, Neuropathy, Painful
- Trial name
- NCT05291975
- Testing
- Erchonia® EVRL™
- Where
- 4 sites in United States
- Volunteers
- 64 people
- Sponsor
- Erchonia Corporation
Diabetic Neuropathies, Depressive Disorder, Major
Duloxetine in Patients With Diabetic in Peripheral Neuropathic Pain With or Without Co-morbid Major Depressive Disorder
The primary objective is to evaluate, separately in diabetic polyneuropathic pain (DPNP) patients with and without co-morbid major depressive disorder (MDD), whether duloxetine given as 60 mg to 120 mg once daily (QD) leads to a…
- Trial name
- NCT00844194
- Testing
- Duloxetine 60 mg QD, Duloxetine 30 mg QD, Duloxetine 90 mg QD
- Where
- 25 sites in Germany
- Volunteers
- 108 people
- Sponsor
- Boehringer Ingelheim
Chronic Pain, Diabetic Neuropathies
Cebranopadol Efficacy and Safety in Diabetic Patients Suffering From Chronic Pain Caused by Damage to the Nerves
The purpose of this trial is to evaluate if cebranopadol is safe and can decrease pain in patients when compared to placebo (a tablet that does not contain active product) and when compared to a marketed product containing…
- Conditions
- Chronic Pain, Diabetic Neuropathies, Diabetes Mellitus
- Trial name
- NCT01939366
- Testing
- Cebranopadol 100 µg, Cebranopadol 300 µg, Cebranopadol 600 µg
- Where
- 82 sites in United States, Austria and 6 more
- Volunteers
- 699 people
- Sponsor
- Tris Pharma, Inc.
Diabetic Neuropathies, Pain
The Effects of the Magnetic Molecular Energizer (MME) on Diabetic Peripheral Neuropathy
This study is intended to demonstrate that exposure to a high intensity, DC electromagnetic field, as supplied by the investigational device known as the Molecular Magnetic Energizer (MME), will create a clinically meaningful…
- Conditions
- Diabetic Neuropathies, Pain, Neuralgia
- Trial name
- NCT00134524
- Testing
- MME procedure
- Where
- 5 sites in United States
- Volunteers
- 100 people
- Sponsor
- Advanced Magnetic Research Institute International
Diabetic Peripheral Neuropathic Pain
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine in participants with pain associated with diabetic peripheral neuropathy (DPN).
- Trial name
- NCT07231419
- Testing
- Suzetrigine
- Where
- 75 sites in United States
- Volunteers
- 734 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Peripheral Neuropathy, Painful Diabetic Neuropathy
A 24-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Peripheral Neuropathy
This is a randomized outpatient, double-blind, placebo-controlled, multiple-site study of the safety, tolerability, and exploratory efficacy of topically administered WST-057 (4% pirenzepine free base monohydrate) for 24 weeks in…
- Conditions
- Peripheral Neuropathy, Painful Diabetic Neuropathy, Diabetic Neuropathies, Painful
- Trial name
- NCT04005287
- Testing
- WST-057 (4% pirenzepine) Lose Dose 2mL, WST-057 (4% pirenzepine) High Dose 4mL
- Where
- 5 sites in Canada
- Volunteers
- 58 people
- Sponsor
- WinSanTor, Inc
Diabetic Polyneuropathy
Painful Diabetic Polyneuropathy Trial With a New Centrally Acting Analgesic
The purpose of this trial is to determine whether the new centrally active analgesic and MS Continus® are effective in the treatment of painful diabetic polyneuropathy.
- Trial name
- NCT00878293
- Testing
- GRT6005, MS Continus®
- Where
- 4 sites in Germany, United Kingdom
- Volunteers
- 90 people
- Sponsor
- Tris Pharma, Inc.
Diabetic Neuropathies
A Study on the Efficacy and Safety of Gabapentin in the Treatment of Patients With Painful Diabetic Neuropathy
The purpose of this study was to evaluate the efficacy, safety, and tolerability of gabapentin for the treatment of patients with painful diabetic neuropathy. The quality of life of all treated patients was also assessed.
- Trial name
- NCT00644748
- Testing
- gabapentin
- Where
- 10 sites in Brazil
- Volunteers
- 95 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Painful Diabetic Neuropathy
Comparison of 10 kHz SCS Combined With CMM to CMM Alone in the Treatment of Neuropathic Limb Pain
This post-market study is being conducted to document comparative safety, clinical effectiveness, and cost-effectiveness of the addition of HF10™ therapy to CMM compared with CMM alone in subjects with chronic, intractable…
- Trial name
- SENZA-PDN (NCT03228420)
- Testing
- Senza HF10 Therapy, CMM
- Where
- 4 sites in United States
- Volunteers
- 430 people
- Sponsor
- Nevro Corp
Diabetic Neuropathies
Trial to Assess the Efficacy and Safety of SPM 927 (200, 400, and 600mg/Day) in Subjects With Painful Distal Diabetic Neuropathy
This phase 3 trial is being conducted at approximately 80 sites in the United States (U.S.) to investigate whether lacosamide (SPM 927) at different doses reduces pain in subjects with diabetic neuropathy.
- Trial name
- NCT00135109
- Testing
- SPM 927
- Where
- United States
- Volunteers
- 654 people
- Sponsor
- UCB Pharma
Diabetic Neuropathy, Painful
Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Pain Associated With Diabetic Peripheral Neuropathy
To evaluate the efficacy and safety of pregabalin at 300 mg/day and 600 mg/day (BID) in patients with painful diabetic peripheral neuropathy.
- Trial name
- NCT00553475
- Testing
- pregabalin
- Where
- 49 sites in Japan
- Volunteers
- 314 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.